摘要：目的 研究甲状腺癌组织中趋化因子4受体(CXCR4)和趋化因子7受体(CXCR7)的表达情况及临床病理意义。方法 选取2012年5月至2014年6月期间在本院进行外科手术的83例甲状腺癌患者及2014年45例甲状腺腺瘤患者，采用免疫组织化学染色方法检测甲状腺腺瘤及甲状腺癌中CXCR4和CXCR7表达。结果 CXCR4和CXCR7在甲状腺癌中的表达阳性率均明显高于甲状腺腺瘤(P＜0.05)。CXCR4和CXCR7在临床分期为Ⅲ～Ⅳ期的甲状腺癌患者中的表达阳性率均明显高于临床分期为I～Ⅱ期者(P＜0.05)；CXCR7在有淋巴结转移的甲状腺癌患者中的表达阳性率明显高于无淋巴结转移者(P＜0.05)，而CXCR4的表达阳性率与甲状腺癌患者有无淋巴结转移无关(P＞0.05)；CXCR4和CXCR7在甲状腺癌组织中的表达阳性率与甲状腺癌患者性别无关(P＞0.05)。在甲状腺癌患者中，CXCR4阳性表达和CXCR7阳性表达呈正相关（r=0.49，P＜0.01）；在甲状腺腺瘤患者中，CXCR4阳性表达和CXCR7阳性表达不相关（r=0.14，P=0.21））。结论 CXCR4和CXCR7参与了甲状腺癌的进展，并为临床上甲状腺癌诊断及靶向治疗提供理论基础。

Abstract：Objective To explore the expressions of chemokine receptor CXCR4 and CXCR7 in thyroid cancer and its clinicopathologic significance. Method 83 patients with thyroid cancer and 45 patients with thyroid adenoma were selected. The expressions of CXCR4 and CXCR7 were detected in all the selected cases samples by immunohistochemical SP technique. Results The positive expression rates of CXCR4 and CXCR7 in the thyroid cancer were higher than those in the thyroid adenoma (P＜0.05), in which the thyroid cancer with clinical stage Ⅲ~Ⅳwere higher than those of the clinical stage I~II (P＜0.05). The positive expression rate of CXCR7 in the thyroid cancer with lymph node metastasis was higher than that of the thyroid cancer without lymph node metastasis (P＜0.05), which of CXCR4 in the patients with thyroid cancer was independent of lymph node metastasis (P＞0.05). The expression of CXCR4 and CXCR7 were also independent of gender of the patients with thyroid cancer (P＞0.05). The positive expressions of CXCR7 in all the patients with thyroid cancer was positively correlated with CXCR4（r=0.49，P＜0.01), while poorly correlated was seen in thyroid adenoma（r=0.14，P=0.21）. Conclusion CXCR4 and CXCR7 are involved in the coordination of thyroid cancer progression. They could be used as prognostic indicators of thyroid cancer.